[HTML][HTML] Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics
FM de Man, AKL Goey, RHN van Schaik… - Clinical …, 2018 - Springer
Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …
[引用][C] Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
FM de Man, AKL Goey, RHN van Schaik… - Clinical …, 2018 - cir.nii.ac.jp
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics,
and Pharmacogenetics | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …
and Pharmacogenetics | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
FM de Man, AKL Goey, RHN van Schaik… - Clinical …, 2018 - europepmc.org
Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
F de Man, AKL Goey, R van Schaik… - Clinical …, 2018 - repub.eur.nl
Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
FM de Man, AKL Goey, HN Ron… - Clinical …, 2018 - search.proquest.com
Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
FM De Man, AKL Goey, RHN Van Schaik… - Clinical …, 2018 - hero.epa.gov
Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …
[HTML][HTML] Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
FM de Man, AKL Goey, RHN van Schaik… - Clinical …, 2018 - ncbi.nlm.nih.gov
Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
FM de Man, AKL Goey… - Clinical …, 2018 - pubmed.ncbi.nlm.nih.gov
Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …
[PDF][PDF] Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
FM de Man, AKL Goey, RHN van Schaik… - 2018 - core.ac.uk
Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
FM de Man, AKL Goey, RHN van Schaik… - Clinical …, 2018 - europepmc.org
Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …